The Effect of Rilonacept versus Placebo on Health-Related Quality of Life in Patients with Poorly Controlled Familial Mediterranean Fever

Objective. To examine the effect of rilonacept on the health-related quality of life (HRQoL) in patients with poorly controlled familial Mediterranean fever (FMF). Methods. As part of a randomized, double-blinded trial comparing rilonacept and placebo for the treatment of FMF, patients/parents completed the modified Child Health Questionnaire (CHQ) at baseline, and at the start and end of each of 4 treatment courses, 2 each with rilonacept and placebo. Results. Fourteen subjects were randomized; mean age was 24.4 ± 11.8 years. At baseline the physical HRQoL score was significantly less (24.2 ± 49.5) but the psychosocial score was similar to the population norm (49.5 ± 10.0). There were significant improvements in most HRQoL concepts after rilonacept but not placebo. Significant differences between rilonacept and placebo were found in the physical (33.7 ± 16.4 versus 23.7 ± 14.5, P = 0.021) but not psychosocial scores (51.4 ± 10.3 versus 49.8 ± 12.4, P = 0.42). The physical HRQoL was significantly impacted by the treatment effect and patient global assessment. Conclusion. Treatment with rilonacept had a beneficial effect on the physical HRQoL in patients with poorly controlled FMF and was also significantly related to the patient global assessment. This trial is registered with ClinicalTrials.gov Identifier NCT00582907.

[1]  Ş. Şahin,et al.  Assesment life quality of familial Mediterranean fever patients by short form-36 and its relationship with disease parameters. , 2013, European review for medical and pharmacological sciences.

[2]  S. Sendur,et al.  Quality of life in adult patients with Familial Mediterranean fever living in Germany or Turkey compared to healthy subjects: a study evaluating the effect of disease severity and country of residence , 2013, Rheumatology International.

[3]  M. Weisman,et al.  Rilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean Fever , 2012, Annals of Internal Medicine.

[4]  G. Yenokyan,et al.  Triggers for attacks in familial Mediterranean fever: application of the case-crossover design. , 2012, American journal of epidemiology.

[5]  P. Hawkins,et al.  Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study , 2011, Arthritis research & therapy.

[6]  G. Alaylı,et al.  Frequency of juvenile fibromyalgia syndrome in children with familial Mediterranean fever: effects on depression and quality of life. , 2011, Clinical and experimental rheumatology.

[7]  A. Martini,et al.  Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. , 2010, The Journal of pediatrics.

[8]  B. Goker,et al.  Health-related quality of life and its associations with mood condition in familial Mediterranean fever patients , 2011, Rheumatology International.

[9]  Isabelle Touitou,et al.  Familial mediterranean Fever in the world. , 2009, Arthritis and rheumatism.

[10]  J. Varni,et al.  Health-related quality of life of school-age children with familial Mediterranean fever. , 2009, Clinical and experimental rheumatology.

[11]  E. Ben-Chetrit,et al.  Non-response to colchicine in FMF--definition, causes and suggested solutions. , 2008, Clinical and experimental rheumatology.

[12]  S. U. Kaymak,et al.  Selective serotonin reuptake inhibitors reduce the attack frequency in familial mediterranean Fever. , 2007, The Tohoku journal of experimental medicine.

[13]  M. Eki̇m,et al.  Possible effect of subclinical inflammation on daily life in familial Mediterranean fever , 2006, Clinical Rheumatology.

[14]  Hypermobility and fibromyalgia frequency in childhood familial Mediterranean fever. , 2004, Clinical and experimental rheumatology.

[15]  R. Gershoni-baruch,et al.  Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. , 2004, Seminars in arthritis and rheumatism.

[16]  Y. Gidron,et al.  Psychosocial Correlates of Incidence of Attacks in Children with Familial Mediterranean Fever , 2003, Journal of Behavioral Medicine.

[17]  A. Panossian,et al.  Double-blind, placebo-controlled, randomized, pilot clinical trial of ImmunoGuard--a standardized fixed combination of Andrographis paniculata Nees, with Eleutherococcus senticosus Maxim, Schizandra chinensis Bail. and Glycyrrhiza glabra L. extracts in patients with Familial Mediterranean Fever. , 2003, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[18]  S. Cavuto,et al.  Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. , 2001, Clinical and experimental rheumatology.

[19]  A. Bolotin,et al.  Living with a child with familial Mediterranean fever: does it affect the quality of life of the parents? , 2000, Clinical and experimental rheumatology.

[20]  Jacques Demaille,et al.  A candidate gene for familial Mediterranean fever , 1997, Nature Genetics.

[21]  F. Collins,et al.  Ancient Missense Mutations in a New Member of the RoRet Gene Family Are Likely to Cause Familial Mediterranean Fever , 1997, Cell.

[22]  M. Pras,et al.  Quality of life of patients with familial Mediterranean fever. , 1997, Clinical and experimental rheumatology.

[23]  M. Pras,et al.  Fibromyalgia in familial Mediterranean fever. , 1994, The Journal of rheumatology.

[24]  Wellbutrin,et al.  Prescribing Information , 2015, European journal of haematology.

[25]  D. Zemer,et al.  Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. , 1986, The New England journal of medicine.

[26]  S. Goldfinger.  Colchicine for familial Mediterranean fever. , 1972, The New England journal of medicine.

[27]  D. Alling,et al.  Colchicine therapy for familial mediterranean fever. A double-blind trial. , 1974, The New England journal of medicine.

[28]  B. Modan,et al.  A controlled trial of colchicine in preventing attacks of familial mediterranean fever. , 1974, The New England journal of medicine.

[29]  E. Sohar,et al.  FAMILIAL MEDITERRANEAN FEVER , 1959, Definitions.